KESTREL Trial for Dual Immunotherapy in Head and Neck Cancer – Cancer Therapy Advisor
Cancer Therapy Advisor |
KESTREL Trial for Dual Immunotherapy in Head and Neck Cancer
Cancer Therapy Advisor Researchers are recruiting participants with recurrent/metastatic HNSCC to evaluate durvalumab with or without tremelimumab. Title: A Phase 3 Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab … |
